randomis
doubleblind
placebocontrol
multicentr
studi
intrathec
administ
natur
human
fibroblast
interferon
ifnb
effect
reduc
exacerb
multipl
sclerosi
ms
patient
exacerbatingremit
diseas
mean
reduct
exacerb
rate
patient
receiv
ifnb
recipi
significantli
greater
studi
patient
receiv
placebo
p
prestudi
exacerb
rate
compar
recipi
control
rate
end
studi
significantli
lower
recipi
control
p
ifnb
given
nine
ten
lumbar
punctur
first
month
studi
patient
observ
continu
year
ifnb
well
toler
recipi
sideeffect
experienc
clearli
accept
benefit
achiev
low
dose
indomethacin
reduc
toxic
ifnb
play
import
role
success
doubleblind
report
result
open
preliminari
studi
suggest
intrathec
administ
natur
human
fibroblast
interferon
ifnb
reduc
exacerb
multipl
sclerosi
ms
patient
rational
present
part
annual
meet
intern
societi
interferon
research
espoo
finland
sept
administ
ifnb
patient
includ
evid
viral
immunopatholog
aetiolog
diseas
known
potent
antivir
immunomodulatori
action
ifnb
given
intrathec
interferon
effect
cross
bloodbrain
barrier
reach
central
nervou
system
cn
administ
system
safe
given
intrathec
sinc
carri
randomis
doubleblind
placebocontrol
multicentr
studi
includ
time
mani
patient
preliminari
studi
determin
definit
whether
intrathec
administ
ifnb
benefici
ms
studi
monitor
throughout
unit
state
nation
institut
health
studi
patient
met
clinic
laboratori
criteria
diagnosi
definit
exacerb
remit
diseas
stabl
progress
high
prestudi
exacerb
rate
least
per
year
prestudi
durat
ill
least
year
patient
month
month
includ
clearli
ms
recent
revis
high
exacerb
rate
patient
underw
complet
neurolog
examin
begin
studi
sever
symptom
sign
score
accord
modifi
kurtzk
method
prestudi
exacerb
rate
determin
divid
total
number
exacerb
standard
definitionz
deg
record
studi
durat
diseas
time
randomis
patient
ms
less
year
number
exacerb
record
studi
consid
number
would
occur
full
year
ie
adjust
rate
upward
compens
shorter
diseas
durat
patient
randomli
assign
bias
coin
recipi
control
group
mean
stratif
base
prestudi
exacerb
rate
ie
less
two
exacerbationsyear
two
exacerbationsyear
randomis
yield
recipi
control
popul
similar
mean
prestudi
exacerb
rate
recipi
control
per
year
meaning
differ
clinic
paramet
two
group
eg
age
sex
prestudi
diseas
durat
disabl
statu
function
group
score
patient
reexamin
regularli
whenev
felt
might
exacerb
exacerb
clinic
disabl
statu
function
group
score
overal
assess
patient
clinic
condit
improv
unchang
worsen
record
exacerb
treat
intramuscular
intraven
corticotropin
daili
day
treatment
may
limit
sever
symptom
sign
exacerb
prevent
recurr
exacerb
rate
studi
calcul
number
exacerb
occur
studi
time
studi
onetail
statist
use
test
effect
treatment
chang
exacerb
rate
statist
plan
base
data
preliminari
studi
design
detect
true
differ
exacerbationr
reduct
recipi
control
exacerb
per
year
type
error
level
power
ifnb
use
produc
superinduct
human
fibroblast
cell
roswel
park
memori
institut
buffalol
prepar
specif
activ
x
interferon
refer
unit
ifnb
per
mg
protein
type
use
preliminari
studi
pass
toxic
safeti
test
requir
food
drug
administr
fda
ind
ifnb
given
recipi
serial
lumbar
punctur
carri
weekli
first
week
month
next
month
studi
ie
nine
lumbar
punctur
first
month
studi
dose
recipi
x
interferon
refer
unit
treatment
except
one
centr
patient
receiv
two
halfdos
treatment
first
week
x
interferon
refer
unit
treatment
ie
ten
lumbar
punctur
first
month
studi
cerebrospin
fluid
csf
withdrawn
analysi
inject
ifnb
lumbar
punctur
recipi
also
underw
lumbar
punctur
year
studi
csf
could
obtain
analysi
control
patient
underw
placebo
treatment
accord
schedul
recipi
howev
true
lumbar
punctur
carri
begin
month
year
studi
obtain
csf
analysi
remaind
fals
lumbar
punctur
routin
procedur
eg
posit
drape
skin
cleans
local
anaesthet
follow
needl
advanc
subcutan
tissu
ml
steril
water
inject
recipi
took
indomethacin
mg
everi
h
h
treatment
control
took
indomethacin
dose
placebo
capsul
accord
schedul
indomethacin
administ
known
reduc
sideeffect
intrathec
interferon
help
blind
patient
treatment
carri
treat
physician
outpati
treatment
room
centr
afterward
patient
vital
sign
monitor
initi
subsequ
examin
assess
exacerb
clinic
statu
carri
separ
examin
physician
centr
awar
treatment
patient
receiv
patient
discuss
sideeffect
treatment
examin
physician
questionnair
complet
patient
examin
physician
studi
confirm
group
blind
chisquar
statist
base
x
tabl
test
independ
individu
impress
ifnb
placebo
unknown
actual
therapi
receiv
yield
examin
physician
p
patient
questionnair
also
reveal
patient
opinion
believ
receiv
ifnb
recipi
control
figur
show
exacerb
rate
studi
two
group
patient
exacerb
rate
group
fell
studi
recipi
mean
sem
per
year
control
per
year
howev
chang
significantli
greater
recipi
control
v
deg
exacerb
per
year
p
greater
reduct
rate
recipi
compar
control
consist
observ
three
centr
mean
prestudi
rate
recipi
control
nearli
ident
recipi
mean
rate
studi
significantli
lower
control
interferon
placebo
mean
exacerb
rate
exacerbationsyear
studi
recipi
control
ms
vertic
bar
repres
alfn
reduct
recipi
rate
pla
reduct
placebo
control
studi
p
correl
analysi
reveal
exacerb
rate
studi
strongli
depend
directli
proport
prestudi
rate
control
p
recipi
r
clinic
recipi
control
improv
unchang
recipi
control
wors
end
studi
extent
deterior
greatest
control
mean
modifi
kurtzk
score
increas
control
recipi
howev
trend
recipi
clinic
stabl
better
control
clinic
wors
statist
signific
chisquar
p
sideeffect
treatment
headach
nausea
myalgia
lethargi
occur
compar
frequenc
recipi
control
may
attribut
least
partli
efficaci
indomethacin
reduc
ifnb
sideeffect
lowgrad
fever
mean
deg
c
occur
often
recipi
control
chisquar
p
deg
break
doubleblind
see
pleocytosi
rise
csf
protein
occur
recipi
treatment
maximum
pleocytosi
mean
rang
x
rise
protein
mean
rang
note
first
week
treatment
last
treatment
month
mean
pleocytosi
x
rang
x
mean
csf
protein
mgjl
rang
year
mean
pleocytosi
x
rang
x
mean
csf
protein
rang
known
exacerb
rate
ms
patient
may
fall
time
natur
phenomenon
howev
studi
chang
exacerb
rate
ms
show
patient
enter
studi
ill
durat
year
recipi
year
control
decreas
rate
would
expect
either
group
studi
natur
phenomenon
therefor
attribut
reduct
exacerb
rate
recipi
ifnb
treatment
also
attribut
uncoupl
depend
rate
studi
prestudi
rate
observ
recipi
control
ifnb
treatment
reduct
exacerb
rate
observ
control
studi
might
due
placebo
effect
continu
followup
patient
studi
preliminari
studi
ifnb
prophylact
effect
exacerb
persist
mdash
year
without
emphasis
treatment
schedul
may
optimum
one
preliminari
studi
patient
underw
thirteen
treatment
month
number
reduc
nine
studi
regimen
significantli
reduc
exacerb
rate
possibl
even
fewer
treatment
differ
interv
might
provid
similar
degre
prophylaxi
